To evaluate the dynamics of retinal fluid in eyes compromised by exudative macular neovascularization beneath the retinal pigment epithelium (MNV type 1) secondary to neovascular age-related macular degeneration (nAMD) and its impact on disease control over time.
Methods
In this retrospective single center study, 65 eyes of 65 patients with treatment-naive exudative MNV Type 1 were analyzed for the presence of subretinal fluid (SRF) and intraretinal fluid (IRF) in structural OCT B-scans for three years. All eyes started on three monthly intravitreal anti-VEGF injections followed by a personalized treatment interval. Primary outcome measure was visual acuity score (VAS) change based on fluid dynamics.
Results
29 (45%) eyes with SRF only started with a VAS of 74 ± 9 letters ETDRS, 20 eyes (31%) with SRF in the beginning that developed additional IRF had an initial VAS of 68 ± 11 letters, and 16 eyes (25%) with both, SRF and IRF measured 63 ± 13 letters at presentation. The VAS of all patients declined significantly (p = 0.003) over time, but no significant VAS change was measured between the groups.
Conclusion
IRF was regarded as a negative predictive OCT biomarker towards a lower VAS at the beginning but not necessarily during the course of the disease.
WongWLSuXLiX, et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health2014; 2: e106–e116.
2.
ChanHHFeoACabralD, et al.Type 4 macular neovascularization (NV): a new member of the optical coherence tomography (OCT) classification of NV age-related macular degeneration (AMD). Retina2026; 46(2): 209–219. DOI: 10.1097/IAE.0000000000004664
3.
ShirleyM. Faricimab: first approval. Drugs2022; 82: 825–830. doi:10.1007/s40265-022-01713-3.
4.
LanzettaPKorobelnikJFHeierJS, et al.Intravitreal aflibercept 8mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet2024; 403: 1141–1152. doi:10.1016/S0140-6736(24)00063-1.
5.
JungJJChenCYMrejenS, et al.The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol2014; 158: 769–779.e2. doi:10.1016/j.ajo.2014.07.006.
6.
SpaideRFJaffeGJSarrafD, et al.Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology2020; 127: 616–636. doi:10.1016/j.ophtha.2019.11.004.
7.
FreundKBZweifelSAEngelbertM. Do we need a new classification for choroidal neovascularization in age-related macular degeneration?Retina2010; 30: 1333–1349. doi:10.1097/IAE.0b013e3181e7976b.
8.
RosenfeldPJBrownDMHeierJS, et al.Ranibizumab for neovascular age-related macular degeneration. N Engl J Med2006; 355: 1419–1431. doi:10.1056/NEJMoa054481.
9.
SharmaAKumarNParachuriN, et al.Understanding the mechanisms of fluid development in age-related macular degeneration. Ophthalmol Retina2021; 5: 105–107. doi:10.1016/j.oret.2020.09.016.
10.
Schmidt-ErfurthUBogunovicHSadeghipourA, et al.Machine learning to analyze the prognostic value of current imaging biomarkers in neovascular age-related macular degeneration. Ophthalmol Retina2018; 2: 24–30. doi:10.1016/j.oret.2017.03.015.
11.
KodjikianLParravanoMClemensA, et al.Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye2021; 35: 2119–2135. doi:10.1038/s41433-021-01487-0.
12.
MetrangoloCDonatiDMazzolaM, et al.OCT Biomarkers in neovascular age-related macular degeneration: a narrative review. J Ophthalmol2021: 9994098. DOI: 10.1155/2021/9994098
13.
AhmedDStattinMHaasAM, et al.The diagnostic capability of swept source OCT angiography in treatment-naive exudative neovascular age-related macular degeneration. J Ophthalmol2021: 6695918. DOI: 10.1155/2021/6695918
14.
StattinMForsterJAhmedD, et al.Seven-year visual and anatomical outcomes of intravitreal vascular endothelial growth factor inhibition for neovascular age-related macular degeneration. J Ophthalmol2020: 8345850. DOI: 10.1155/2020/8345850
15.
WaldsteinSMSimaderCStaurenghiG, et al.Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology2016; 123: 1521–1529. doi:10.1016/j.ophtha.2016.03.037.
16.
BhuttoIABabaTMergesC, et al.C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration. Br J Ophthalmol2011; 95: 1323–1330. doi:10.1136/bjo.2010.199216.
17.
AmbatiJFowlerBJ. Mechanisms of age-related macular degeneration. Neuron2012; 75: 26–39. doi:10.1016/j.neuron.2012.06.018.
18.
Dhrami-GavaziEBalaratnasingamCLeeW, et al.Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration. Int J Retina Vitreous2015; 1: 15. doi:10.1186/s40942-015-0015-6.
19.
GuymerRHMarkeyCMMcAllisterIL, et al.Tolerating subretinal fluid in neovascular agerelated macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology2019; 126: 723–734. doi:10.1016/j.ophtha.2018.11.025.
20.
GrechenigCReiterGSRiedlS, et al.Impact of residual subretinal fluid volumes on treatment outcomes in a SRF-tolerant treat & extend regimen. Retina2021; 41: 2221–2228. doi:10.1097/IAE.0000000000003180.
21.
Schmidt-ErfurthUWaldsteinSM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res2016; 50: 1–24. doi:10.1016/j.preteyeres.2015.07.007.
22.
CoreJQPistilliMDanielE, et al.Predominantly persistent subretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retina2021; 5: 962–974. doi:10.1016/j.oret.2021.06.003.
23.
SharmaSTothCADanielE, et al.Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology2016; 123: 865–875. doi:10.1016/j.ophtha.2015.12.002.
24.
ZurDGuymerRKorobelnikJF, et al.Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration. Br J Ophthalmol2025; 109: 307–315. doi:10.1136/bjo-2024-325640.
25.
CoreJQPistilliMHuaP, et al.Predominantly persistent intraretinal fluid in the comparison of age-related macular degeneration treatments trial. Ophthalmol Retina2022; 6: 771–785. doi:10.1016/j.oret.2022.03.024.
26.
Schmidt-ErfurthUWaldsteinSMDeakGG, et al.Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology2015; 122: 822–832. doi:10.1016/j.ophtha.2014.11.017.
27.
DomalpallyADanisRPWhiteJ, et al.Circularity index as a risk factor for progression of geographic atrophy. Ophthalmology2013; 120: 2666–2671. doi:10.1016/j.ophtha.2013.07.047.
28.
HeierJSBrownDMChongV, et al.Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology2012; 119: 2537–2548. doi:10.1016/j.ophtha.2012.09.006.
29.
Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology2016; 123: 1751–1761. doi:10.1016/j.ophtha.2016.03.045.
30.
LekJJCarusoEBaglinEK, et al.Interpretation of subretinal fluid using OCT in intermediate age-related macular degeneration. Ophthalmol Retina2018; 2: 792–802. doi:10.1016/j.oret.2018.01.005.
31.
HilelyAAuAFreundKB, et al.Non-neovascular age-related macular degeneration with subretinal fluid. Br J Ophthalmol2021; 105: 1415–1420. doi:10.1136/bjophthalmol-2020-317326.
32.
ServilloAKesimCSacconiR, et al.Non-exudative intraretinal fluid in intermediate age-related macular degeneration. Retina2024; 44: 997–1005. doi:10.1097/IAE.0000000000004054.
33.
CohenSYDuboisLNghiem-BuffetS, et al.Retinal pseudocysts in age-related geographic atrophy. Am J Ophthalmol2010; 150: 211–217.e.1. doi:10.1016/j.ajo.2010.02.019.
34.
MeneanMSacconiRVujosevicS, et al.Subretinal pseudocysts: a comprehensive analysis of this novel OCT finding. Ophthalmol Ther2023; 12: 2035–2048. doi:10.1007/s40123-023-00727-8.
35.
NaritaCWuZRosenfeldPJ, et al.Structural OCT signs suggestive of subclinical nonexudative macular neovascularization in eyes with large drusen. Ophthalmology2020; 127: 637–647. doi:10.1016/j.ophtha.2019.11.007.
QuartaAFeoACorradettiG, et al.Double layer sign in chorioretinal diseases: clinical significance and implications from multimodal imaging. Surv Ophthalmol2025; 20: S0039-6257(25)00179-1. doi:10.1016/j.survophthal.2025.09.017.
38.
CsincsikLMuldrewKABettiolA, et al.The double layer sign is highly predictive of progression to exudation in age-related macular degeneration. Ophthalmol Retina2024; 8: 234–245. doi:10.1016/j.oret.2023.10.006.
39.
PauleikhoffDGunnemannMLZieglerM, et al.Morphological changes of macular neovascularization during long-term anti-VEGF-therapy in neovascular age-related macular degeneration. PLoS One2023; 18: e0288861. doi:10.1371/journal.pone.0288861.
40.
AlhelalyMSoyluCCorradettiG, et al.In vivo characterization of Bruch's membrane breaks in neovascular age-related macular degeneration using high-resolution optical coherence tomography. Invest Ophthalmol Vis Sci2025; 66: 19. doi:10.1167/iovs.66.9.19.
41.
RuggeriMLTotoLZeppaL, et al.Impact of vitreomacular interface on intravitreal Brolucizumab efficacy in age-related macular neovascularization. Eur J Ophthalmol2025; 35: 1005–1012. doi:10.1177/11206721241282429.
42.
SharmaAKumarNSinghS, et al.Management of fluid in neovascular age-related macular degeneration: to mop it, to dab it, or to leave it?Retina2020; 40: 1451–1455. doi:10.1097/IAE.0000000000002870.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
